Rakovina Therapeutics Moves to Bolster Finances With Debenture Deal, Equity Raise and Debt Overhaul

Rakovina Therapeutics Inc ( (TSE:RKV) ) has provided an update.

Rakovina Therapeutics has outlined a multifaceted corporate plan combining new financing, leadership changes and debt restructuring to support its near-term operations and strengthen its capital markets profile. The company has secured debentureholder consent to extend the maturity of its outstanding 12% convertible debentures from January 28, 2026, to March 11, 2026, as part of a broader proposed restructuring that would allow current holders to exchange into new debentures on substantially similar terms to a planned 2026 instrument or convert debt and accrued interest into equity at a set share price, subject to regulatory and TSX Venture Exchange approvals. In parallel, Rakovina has reached an agreement in principle with an existing debenture investor for a new $1.0 million unsecured convertible debenture financing maturing in 2029, with a 12% coupon, equity conversion features and attached warrants, and is also pursuing an additional $500,000 common share private placement. Collectively, these measures are designed to stabilize the balance sheet, extend the company’s financial runway and enhance governance and capital markets execution as it advances its oncology pipeline, though the transactions remain contingent on final terms, shareholder choices and regulatory clearance.

More about Rakovina Therapeutics Inc

Rakovina Therapeutics Inc. is a Vancouver-based biopharmaceutical company focused on advancing novel cancer therapies. Listed on the TSX Venture Exchange and the Frankfurt Stock Exchange, the company operates in oncology drug development, targeting innovative treatments that can attract specialized life-sciences investors and strategic partners in the cancer therapeutics market.

Average Trading Volume: 37,471

Technical Sentiment Signal: Sell

Current Market Cap: C$3.38M

See more data about RKV stock on TipRanks’ Stock Analysis page.